Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine

The objective of the present work was to assess the reactogenicity and immunogenicity of heterologous COVID-19 vaccination regimens in clinical trials and observational studies. PubMed, Cochrane Library, Embase, MedRxiv, BioRxiv databases were searched in September 29, 2021. The PRISMA instruction f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2022-03, Vol.147, p.112650-112650, Article 112650
Hauptverfasser:	Nguyen, Thuy Trang, Quach, Trang Ho Thu, Tran, Thanh Mai, Phuoc, Huynh Ngoc, Nguyen, Ha Thi, Vo, Tuong Kha, Vo, Giau Van
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 - therapeutic use Arthralgia - chemically induced BNT162 Vaccine - therapeutic use ChAdOx1 nCoV-19 - therapeutic use COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - therapeutic use Diarrhea - chemically induced Fatigue - chemically induced Fever - chemically induced Headache - chemically induced Humans Immunization, Secondary Immunogenicity Immunogenicity, Vaccine Injection Site Reaction - etiology Myalgia - chemically induced Prime-boost Reactogenicity SARS-CoV-2 Vaccination Vaccine Vaccines, Subunit - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!